SLC35A2-related congenital disorder of glycosylation : Defining the phenotype by Yates, T. Michael et al.
e u r o p e a n j o u rn a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 1 0 9 5e1 1 0 2Official Journal of the European Paediatric Neurology SocietyOriginal articleSLC35A2-related congenital disorder of
glycosylation: Defining the phenotypeT. Michael Yates a, Mohnish Suri b, Archana Desurkar c, Gaetan Lesca d,
Carina Wallgren-Pettersson e, Trine B. Hammer f, Ashok Raghavan g,
Anne-Lise Poulat d, Rikke S. Møller f,h, Ann-Charlotte Thuresson i,
Meena Balasubramanian a,j,*
a Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK
b Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, City Hospital Campus,
Nottingham, UK
c Department of Paediatric Neurology, Sheffield Children's NHS Foundation Trust, Sheffield, UK
d Hospices Civils de Lyon, Service de Genetique, CHU de Lyon, Lyon, France
e Department of Medical and Clinical Genetics, University of Helsinki and the Folkhaelsan Institute of Genetics,
Helsinki, Finland
f The Danish Epilepsy Center Filadelfia, Dianalund, Denmark
g Department of Radiology, Sheffield Children's NHS Foundation Trust, Sheffield, UK
h Institute for Regional Health Research, University of Southern Denmark, Odense, Denmark
i Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala, Uppsala University,
Uppsala, Sweden
j Academic Unit of Child Health, Department of Oncology & Metabolism, University of Sheffield, UKa r t i c l e i n f o
Article history:
Received 30 May 2018
Received in revised form
10 August 2018
Accepted 19 August 2018
Keywords:
Developmental and epileptic en-
cephalopathy
Congenital disorders of glycosyla-
tion
Intellectual disability
SLC35A2* Corresponding author. Sheffield Clinical G
2737467.
E-mail address: meena.balasubramanian
https://doi.org/10.1016/j.ejpn.2018.08.002
1090-3798/© 2018 European Paediatric Neuroa b s t r a c t
We aim to further delineate the phenotype associated with pathogenic variants in the
SLC35A2 gene, and review all published literature to-date. This gene is located on the X
chromosome and encodes a UDP-galactose transporter. Pathogenic variants in SLC35A2
cause a congenital disorder of glycosylation. The condition is rare, and less than twenty
patients have been reported to-date. The phenotype is complex and has not been fully
defined.
Here, we present a series of five patients with de novo pathogenic variants in SLC35A2.
The patients' phenotype includes developmental and epileptic encephalopathy with hyp-
sarrhythmia, facial dysmorphism, severe intellectual disability, skeletal abnormalities,
congenital cardiac disease and cortical visual impairment.
Developmental and epileptic encephalopathy with hypsarrhythmia is present in most
patients with SLC35A2 variants, and is drug-resistant in the majority of cases. Adreno-
corticotropic hormone therapy may achieve partial or complete remission of seizures, but
the effect is usually temporary. Isoelectric focusing of transferrins may be normal after
infancy, therefore a congenital disorder of glycosylation should still be considered as aenetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK. Fax: þ44 114
@nhs.net (M. Balasubramanian).
logy Society. Published by Elsevier Ltd. All rights reserved.
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Patient 1: dysmorphic features include br
proximally placed 2nd toe (L foot). Patien
fissures, mid-face hypoplasia with depre
Patient 3: dysmorphic features include e
prominent eyelashes; broad eyebrows; s
posteriorly-rotated ears. Also note taperi
in this figure legend, the reader is referrdiagnosis in the presence of a suggestive phenotype. We also provide evidence that cortical
visual impairment is part of the phenotypic spectrum.
© 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Over 100 glycosylation-related human genetic disorders have
been reported in the literature. These result fromdisruption of
the normal N-glycosylation pathway which involves adding
complex sugar chains (glycans) to proteins.1 Congenital dis-
orders of glycosylation (CDG) can result in a complex pheno-
type, including intellectual disability and seizures.2,3 Variants
in the SLC35A2 gene (MIM #300896), on the X chromosome,
coding for the only known transporter of UDP-galactose to the
Golgi apparatus, have been found to result in a congenital
disorder of glycosylation.4 To the authors' knowledge, less(c,f,i,j) at ages 11-mont
achycephaly, hypertelo
t 2: dysmorphic featur
ssed nasal bridge, open
longated palpebral fiss
hort nose and hypoplas
ng fingers and broad gr
ed to the Web versionthan twenty patients with variants in this gene have been
reported in detail to-date.3e10 The associated phenotype in-
cludes developmental and epileptic encephalopathy (DEE),
severe intellectual disability (ID), hypotonia, dysmorphic fea-
tures, and shortening of the distal limbs.
Here, we present five new patients with de novo pathogenic
variants in SLC35A2, who have DEE with hypsarrhythmia,
severe ID, skeletal abnormalities and cortical visual impair-
ment. We further define the phenotypic spectrum, in partic-
ular the epilepsy phenotype. With increasing use of next
generation sequencing in patients with epilepsy, it is likely
that more patients will be identified with this phenotype andhs, 8-years and 11-months, and two-years respectively.
rism, and low-set ears. Note 2e3 toe syndactyly (R foot) and
es include high-set eyebrows, long, narrow palpebral
mouth with full, tented upper lip and a protruding tongue.
ures, large blue irises; eversion of the lower lids; long and
tic alae nasi; short, grooved philtrum; tented upper lip and
eat toes. (For interpretation of the references to color/colour
of this article.)
Table 1 e Features of patients in this cohort. Isf Tf isoelectric focusing of transferrins; n/a not applicable; nd not done; AED antiepileptic medication. All variants are
according to the NM_005660.2 transcript.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Gender F F F F F
Age at evaluation (yr; mo) 3 8; 11 8; 0 3; 4 0; 10
SLC35A2 variant (predicted
protein change)
c.889A > G (p.Lys297Glu) c.327T > G (p.Tyr106*) c.195C > A (p.Phe65Leu) c.515T > C (p.Leu172Pro) c.923C > T (p.Ser308Phe)
ACMG pathogenicity criteria PS2, PM2 and PP3
(Likely pathogenic)
PVS1, PS2 (Pathogenic) PS2, PM2, PP3, PP4
(Likely pathogenic)
PS2, PM2 and PP3
(Likely pathogenic)
PS2, PM2, PP2, PP3
(Likely pathogenic)
Family history Cousin X-linked
agammaglobulinaemia
Brother single febrile seizure Unremarkable Unremarkable Unremarkable
Antenatal findings Tetralogy of Fallot Nil Nil Nuchal thickening Nil
Gestational age at birth (weeks) 40 34 43 40 38
Birth weight 50th centile 25e50th centile 25th centile 40th centile 75the91st centile
Admission to NICU Yes e Tetralogy of Fallot Yes eWeight loss, jaundice,
skin ulcers
No No Yes e CPAP
Dev. delay Yes Yes Yes Yes Yes
ID n/a Severe Severe Severe n/a
Age of seizure onset 6 weeks 5 months 6 months 6 weeks Possible at age
4 months
Initial seizure type Infantile spasms Infantile spasms Infantile spasms Infantile spasms Eye rolling/chewing
episodes
Evolving seizure phenotype Myoclonic & tonic seizures;
and ongoing spasms
with clusters
Drop attacks, tonic spasms,
change in visual attention
n/a n/a n/a
EEG Hypsarrhythmia Hypsarrhythmia Hypsarrhythmia Hypsarrhythmia Focalised epileptic
activity
AED response Partial Pharmacoresistant Seizure free, off
medication
Seizure free on Vigabatrin,
Nitrazepam and ketogenic diet
AED stopped with no
clinical change
Dysmorphic Yes Yes Yes Yes Yes
Hypotonia No No Yes Yes Yes
Head circumference
centile (age)
9th (11 mo) <<0.4th (9 yr) 98the99.6th (birth) 40th (3 y 4 mo) 50th (10 mo)
Visual defect Severe cortical visual
impairment
No Myopia, astigmatism,
intermittent exotropia
of the right eye and
amblyopia ex anopsia
No Strabismus
Skeletal abnormality Thoracic scoliosis, bilateral
coxa valga and generalised
osteopenia. Unusual defects
involving the right proximal
and distal tibia, with right tibia
shorter than the left. Possible similar
early changes in the left distal tibia
Bilateral coxa valga with
partial hip subluxation
Joint hypermobility,
genu valga, asymmetric
chest deformity
Camptodactyly of the
2nd right finger
n/a
(continued on next page)
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and potential treatment options in this group of disorders.2. Patient reports
Our cohort consists of five female patients born to non-
consanguineous White European parents (Fig. 1). All patients
had normal chromosomal microarray analysis (Patient 1 was
found to have a paternally inherited 320 kb deletion at 6q26,
classified as likely benign). All were found to have heterozy-
gous de novo variants in SLC35A2 with no additional variants.
Patient 4 was also found to have a skewed X chromosome
inactivation profile (100:0). Three patients had normal iso-
electric focusing of transferrins, performed between the ages
of 2 and 8 years. In addition to the reports here, Table 1 pro-
vides further clinical information. Further details are included
in the supplementary material.
2.1. Patient 1
This 3-year old patient developed infantile spasms at 6-weeks
of age. EEG (electroencephalogram) demonstrated hypsar-
rhythmia.Magnetic Resonance Imaging (MRI) of the brain at 7-
months of age demonstrated asymmetry of the lateral ven-
tricles and a thin corpus callosum (Supp Fig. 1). She had a
partial response to Vigabatrin and Prednisolone. Her seizures
subsequently evolved to myoclonic and tonic seizures in
addition to ongoing spasms with clusters. These were resis-
tant to several different treatment regimens including com-
binations of Vigabatrin, steroids, Sodium Valproate,
Levetiracetam, and Topiramate. Seizure control improved on
classical ketogenic diet therapy at 12-months of age, together
with cessation of all anti-epileptic medications. A course of
ACTH (adrenocorticotropic hormone) therapy resulted in a
definite, but short-lived, improvement in seizure control.
Response to a second course of ACTH was less effective.
She had significant developmental impairment. Tetralogy
of Fallot was noted on antenatal ultrasound (USS), which
subsequently required surgery. On assessment at the age of 3-
years, she was noted to be dysmorphic and had right lower
limb shortening.
Radiological review of a skeletal survey demonstrated
thoracic scoliosis, bilateral coxa valga and generalised osteo-
penia. There were unusual defects involving the right prox-
imal and distal tibia, with the defect in the proximal tibia
being larger. Overall, the right tibia was shorter than the left.
Possible similar early changes were seen in the left distal tibia
(Fig. 2). The significance of these radiological findings remains
uncertain.
She also has severe cortical visual impairment, with no
response to formal visual acuity assessment but some brief
fixation. Electroretinogram (ERG) confirmed no evidence of
diffuse retinal dysfunction.
2.2. Patient 2
This 8-year old patient developed infantile spasms at the age of
5-months. EEG showed hypsarrhythmia and an MRI brain scan
was normal. Initial treatment was with Prednisolone and
Fig. 2 e Patient 1 (aeb): radiographs at 11-months of age demonstrating non-specific defects involving the right proximal
and distal tibia, with the proximal tibia being larger. Patient 2 (c): radiograph of pelvis demonstrates bilateral coxa valga
with partial hip subluxation.
e u r o p e a n j o u rn a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 1 0 9 5e1 1 0 2 1099subsequently Vigabatrin with partial response. Over the course
of the next few years she developed drop attacks, tonic spasms,
and changes in visual attention associatedwith an unusual cry.
Her seizures were resistant to ketogenic diet, as well as
combinations of Lamotrigine, Zonisamide, Nitrazepam, Rufi-
namide, and Topiramate. Repeat EEG at the age of 4-years and
3-months showed hypsarrythmia. Repeat MRI brain imaging
at the ages of 18 and 31 months showed significantly delayed
cerebral white matter myelination. This normalised by age 4-
years, with some residual hyperintensity posterior to the
trigones of the lateral ventricles. The hippocampi appeared
small and malrotated (Supp Fig. 2).
She had severe developmental delay. On assessment at the
age of 8-years she had severe ID and was able to walk a few
stepswith support. Shewas dysmorphic. A pelvis X-ray showed
bilateral coxa valga with partial hip subluxation (Fig. 2).
2.3. Patient 3
This 8-year old patient developed infantile spasms at 6-
months of age. EEG demonstrated hypsarrhythmia. Her sei-
zures responded to Vigabatrin in combination with ACTH. She
was then treated with Valproate monotherapy. From the age
of 3½ years, medication was withdrawn and she remained
seizure-free. Neonatal nystagmuswas noted, which ceased as
seizure control improved. She had myopia, astigmatism,
intermittent exotropia of the right eye and amblyopia ex
anopsia. ERG performed at 14-months of age was normal. MRI
brain and echocardiogram at the age of 8-monthswas normal.
On assessment at the age of 3-years and 4-months, she had
severe hypotonia and severe global developmental delay. She
was dysmorphic. At the age of 8-years, she has severe ID with
no spoken language. She can walk with support if helped to a
standing position.
2.4. Patient 4
This 3-year old patient developed infantile spasms at 6-weeks
of age and EEG demonstrated hypsarrhythmia. Her spasms
were partially controlled with a combination of Vigabatrin,
steroids and ACTH therapy. She was treated unsuccessfully
with Phenobarbital, Valproate, Levetiracetam and Topiramate.
Her spasms ceased with a combination of Vigabatrin, Nitra-
zepam and ketogenic diet at 2-years and 3-months of age.MRI brain scan at two months was normal. A second MRI
brain at 2½ years of age demonstrated thinning of the corpus
callosum with delayed myelination and slight enlargement
of the lateral ventricles. On assessment at 3-years and 4-
months of age, she had global hypotonia. She could sit and
stand with help. She had no spoken language. She had se-
vere ID. She was dysmorphic. There were no ophthalmic
abnormalities.
2.5. Patient 5
This 10-month old patient developed eye rolling and chewing
episodes at the age of four months, as well as unilateral
myoclonic jerks. Therewas one episode of opisthotonus. Focal
epileptic activity was noted on EEG at the age of five months,
however this did not correlate with clinical episodes. Carba-
mazepine and then Levetiracetam monotherapy was trialled,
but did not have a significant effect andwas discontinued.MRI
brain was normal.
On assessment at the age of 10-months, she had moderate
to severe developmental delay. She had hypotonia, and was
dysmorphic. There were no ophthalmic abnormalities.3. Methods
All patients were ascertained through routine referral to their
local Clinical Genetics service. The cohortwas formed through
personal communication (Patient 2), interrogation of the
DECIPHER database11 (Patient 3) and through the Gene-
Matcher website12 (Patients 4 and 5). Genomic DNA was
extracted from peripheral blood leukocytes from patients
using standard procedures. All patients underwent chromo-
somal microarray-analysis. Patients 1e2 and 4e5 were
thought to have epilepsy as a predominant part of their
phenotype. They therefore had targeted epilepsy gene panels
performed. A wider differential was considered for Patient 3,
therefore whole genome sequencing (WGS) was performed.
For patients 1 & 2, sequencing of 72 genes associated with
early infantile epileptic encephalopathy was carried out using
targeted whole exome sequencing (WES) (Agilent SureSelect
and MiSeq). Trio-based WGS was carried out for patient 3
using the Illumina HiSeqX system (Illumina). For patient 4,
sequencing of a 93 gene panel for monogenic epileptic
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 1 0 9 5e1 1 0 21100disorders was performed on a NextSeq500 (Illumina). Analysis
of 569 genes associated with ID, autism and epilepsy was
performed via targeted WES for patient 5 using NovaSeq 6000
Agilent SureSelect All Human Exon v6. All data was analysed
against GRCh37. All variants reported are according to the
NM_005660.2 transcript. Variants were verified by Sanger
sequencing using standard protocols. Methods are described
in further detail in the supplementary material.4. Discussion
We present here a series of five patients with de novo patho-
genic variants in SLC35A2 and phenotypic features including
epilepsy with hypsarrhythmia, severe ID, non-specific dys-
morphism, visual and skeletal abnormalities.
Comparison of our cohort with those previously
reported3e10 allows us to define the phenotype associated
with SLC35A2, particularly in relation to epilepsy, which af-
fects 16/18 (89%) patients (Table 2). Seizures start in early in-
fancy, with 8/11 (73%) of those reported developing before the
age of 3-months and all before 6-months. The presentation
was with infantile spasms in 8/10 (80%). Two patients pre-
sented with tonic seizures and partial motor seizuresTable 2 e Summary of patients with pathogenic SLC35A2 vari
Patient 1 Patient 2 Patient 3 Patient 4
Gender F F F F
Age (yr; mo) 3 8; 11 8; 0 3; 4
Inher. de novo de novo de novo de novo
SLC35A2 variant c.889A > G c.327T > G c.195C > A c.515T > C
Predicted protein
change
p.Lys297Glu p.Tyr106* p.Phe65Leu p.Leu172Pro
Isf Tf (age -yr; mo) Nd nml (8; 11) nml (3; 4) nml (2; 6)
Dev. delay S S S S
ID n/a S S S
Seizures Y Y Y Y
Age seizure onset 6 wk 5 mo 6 mo 6 wk
Initial seizure type Infantile
spasms
Infantile
spasms
Infantile
spasms
Infantile
spasms
Evolving seizure
phenotype
Myoclonic
and tonic þ
ongoing spasms
with clusters
Drop
attacks
þ tonic
spasms
n/a n/a
Seizures ctrl N N Y Y
Hypsarrhythmia Y Y Y Y
Dysmorphism Y Y Y Y
Hypotonia N N Y Y
Microcephaly N Y N N
MRI abn. TC, AV DM N DM, TC
Visual defect CV N RA N
Skeletal abn. SC CV JH, GV N
Brain abnormalities: TC: thin corpus callosum, AV: abnormal ventricles,
Ophthalmic abnormalities: CV: cortical visual impairment, RA: refractive
Skeletal abnormalities: SC: scoliosis, CV: coxa valga, GV: genu valga, SE:
Abbreviations: Inher. e inheritance, yr e year, mo emonths, dn e de novo
Medical Genetics and Genomics e Association for Molecular Pathology, Is
to severe, ctrl e controlled, nd e not documented, Dev e developmental, I
e ophthalmic.respectively. The phenotype was reported, in six patients, to
progress to a combination of tonic seizures plus spasms. Two
patients were also reported to have myoclonic seizures.
Hypsarrhythmia is common (13/16; 81%). Given that all
affected patients have developmental delay, this means most
meet the criteria forWest syndrome (triad of infantile spasms,
hypsarrhythmia and developmental delay). Epilepsy in this
group is usually resistant to treatment with 7/11 (64%) of pa-
tients having ongoing seizures.
There does not appear to be a definite pattern to response
in treatment, but our experience suggests that partial and/or
temporary seizure control may be achieved with either
Vigabatrin ± steroids, the ketogenic diet or ACTH. Four pre-
viously reported patients have had a temporary response to
ACTH, with a further patient achieving seizure control with
this therapy.3,6,7 As these are standard treatments for infantile
spasms, further work is needed to determine optimal epilepsy
medication in this group of patients.
All patients reported have severe ID. None of the five pa-
tients reported here had developed spoken language. Non-
specific dysmorphic features are present in 16/17 (94%). Hy-
potonia (12/18; 67%) and microcephaly (6/13; 46%) are com-
mon. Fifteen out of 18 (83%) patients have abnormalities on
brain MRI. The most common findings are thinning of theants previously reported, including this study cohort.
Patient 5 Ng et al.
(Patient 1)
Ng et al.
(Patient 2)
Ng et al.
(Patient 3)
Kodera et al.
(Patient 1)
F M F M F
0; 10 3 3 6 8; 10
de novo de novo de novo de novo de novo
c.923C > T c.15_91 þ
48delinsA
c.3G > A c.991G > A c.433_434del
p.Ser308Phe p.Gly8Serfs*9 p.Met1? p.Val331Ile p.Tyr145Profs*76
nd abn (0; 5),
nml (3; 2)
abn (0; 7),
nml (2; 9)
abn (0; 5e7),
nml (5; 0)
nml (8; 10)
M-S Y Y Y S
n/a n/a n/a nd S
N Y Y N Y
n/a nd nd nd 6 days
n/a nd nd nd Tonic
n/a nd nd nd Infantile
spasms þ
tonic seizures
n/a nd nd nd N
N Y Y N Y
Y N Y Y Y
Y Y Y Y Y
N N Y Y nd
N Small
cerebellum
DM, TC CA TC, DM, CA
EM EM RA EM N
N N SE SE N
DM: delayed myelination, CA: cerebral/cerebellar atrophy.
error, EM: abnormal eye movements, RA: retinal abnormality.
shortened extremities, HD: hip dislocation, JH: joint hypermobility.
, mat ematernal, Y e yes, N e no, ACMG-AMP e American College of
f Tf e Isoelectric focusing of transferrins, S e severe, M-S emoderate
D e intellectual disability, nml e normal, abn e abnormality, ophthal
e u r o p e a n j o u rn a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 1 0 9 5e1 1 0 2 1101corpus callosum (8/18; 44%), cerebral and/or cerebellar atro-
phy (8/18; 44%) and delayed myelination (6/18; 33%). One pa-
tient in our cohort had a normal MRI brain scan at the age of 8-
months. Interestingly, however, two previously reported pa-
tients3 initially had normal MRI-brain scans in infancy. Sub-
sequent imaging at the ages of 4 and 8 years respectively was
abnormal. Therefore, it is possible that SLC35A2-associated
brain abnormalities develop over time, and this may well
prove to be the case in our patient with an early normal MRI
brain scan.
Visual defects are present in 11/16 (69%) individuals. Of
note, one other patient has been previously reported with
cortical visual impairment,5 although the patient of D€orre
et al.6 had severe visual impairment of unspecified cause.
Therefore, our report provides further evidence that this
specific visual abnormality is part of the phenotypic spectrum
associated with SLC35A2 pathogenic variants. However, it is
also possible that in view of DEE, visual impairment may be a
part of the phenotype rather than a specific issue.
Skeletal abnormalities are found in 9/14 (64%) patients.
Features include short stature, non-specific limb shortening,
scoliosis and bilateral coxa valga. The X-rays of the pelvis in
both patients 1 and 2 showed bilateral coxa valga with high
migration index on both sides, suggesting this may be a spe-
cific finding. Further imaging of patients with SLC35A2 is
required to ascertain the skeletal findings in this group.Kodera et al.
(Patient 2)
Kodera et al.
(Patient 3)
Bosch et al. Kimizu et al. Dorre et al.
F F F F F M
12; 8 10; 5 23 2 5 8
de novo de novo de novo de novo de novo mat
c.972del c.638C > T c.800A > G c.950delG c.797G > T c.772
p.Phe324Leufs*25 p.Ser213Phe p.Tyr267Cys p.Gly317Alafs*32 p.Gly266Val p.Va
nml (12; 8) nml (10; 5) nd mass spectrometry
nml (1; 0), (2; 6)
abn (0; 1), (5; 0) nml
S S Y S S S
S S S n/a nd S
Y Y Y Y Y Y
1 mo 3 mo nd 2 mo 3 mo nd
Infantile
spasms
Infantile
spasms
nd Partial motor
seizures
upper limbs
nd nd
Tonic seizures,
spasms, focal
seizure
Tonic seizure,
spasms
nd Spasms nd nd
N N nd Y Y nd
Y Y nd Y Y N
Y Y Y Y Y Y
N Y Y Y Y N
nd nd Y N Y Y
AV CA, TC DM TC, CA, AV CA, TC CA, T
heter
RA N CV N ‘severe visual
impairment’
nd
N HD SC nd JH ndOur cohort includes one patient with Tetralogy of Fallot.
This has not been reported in association with SLC35A2 and
may represent a novel feature. However, this cardiac abnor-
mality can occur in isolation and further reports are required
to determine if congenital cardiac disease is part of the
SLC35A2 phenotypic spectrum.
Transferrin isoelectric focusing was normal for those
tested in our cohort at ages 3-years 4-months and 2-years 6-
months respectively (Patients 3 & 4). The majority of re-
ported patients, including our cohort, had normal trans-
ferrin profiles after the age of 2-years (Table 2). Ng et al.4
demonstrated galactosylation-deficient transferrin profiles
in their patient series between the ages of 5e7 months, with
normalisation after the age of 3 years. Therefore, there is
likely to be an age-related time period for transferrin testing
in relation to SLC35A2-related CDG, emphasising the
importance of early diagnosis. Ng et al.4 hypothesised this is
related to selection against hepatocytes with abnormal
SLC35A2 during early development; however, this has not
been conclusively demonstrated. Our data suggest that
isoelectric focusing of transferrins is a useful diagnostic test
in females presenting with early onset infantile spasms.
This analysis should be performed before three years of age
if feasible.
SLC35A2 is located on the X chromosome; all of our pa-
tients are females, in keeping with majority of patientsLopes et al. EuroEPINOMICS
et al. (Patient 1)
EuroEPINOMICS
et al. (Patient 2)
Evers et al. Total
(reported)
F F F e
3 13 2 e
de novo de novo mat e
G > A c.683C > A c.502C > T c.831C > G e
l258Met p.Ser228* p.Gln168* p.Asn277Lys e
(8; 0) nd nd abn (2; 0) e
nd S S 17 of 17 (100%)
Y S nd 10 of 10 (100%)
Y Y Y 16 of 18 (89%)
3 mo 4.5 mo nd e
Infantile
spasms
Infantile spasms nd e
Spasms þ
tonic seizures
Myoclonic,
tonic-clonic, tonic
nd e
N N nd 4 of 11 (36%)
Y Y nd 13 of 16 (81%)
Y Y nd 16 of 17 (94%)
Y N N 12 of 18 (67%)
nd nd N 6 of 13 (46%)
C, periventricular
otopia
N DM, CA CA 15 of 18 (83%)
nd EM Cataract 11 of 16 (69%)
nd SC nd 9 of 14 (64%)
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 2 ( 2 0 1 8 ) 1 0 9 5e1 1 0 21102reported thus far. Ng et al.4 reported two male patients who
were mosaic for SLC35A2 pathogenic variants. It is likely that
the presence of a functional allele is required for survival.
There have been two reports of maternal inheritance in the
literature8,10; otherwise all the pathogenic variants reported
are de novo. Our cohort includes three novel missense variants
and one novel nonsense variant. Overall, including our cohort,
missense and truncating variants have been reported in the
literature at approximately equal frequency.
In summary, we present a series of five patients with
pathogenic SLC35A2 variants and review the features of pa-
tients previously reported, with particular focus on the drug-
resistant epilepsy phenotype and MRI brain findings. This al-
lows us to further define the phenotype of this rare disorder.
Early onset epilepsy presenting with infantile spasms and
hypsarrhythmia predominates, in association with severe
developmental delay and ID. Interestingly, severe early-onset
epilepsy is unusual in CDGs in general. This appears to be a
feature unique to SLC35A2-related CDG.
Additional common features include non-specific dys-
morphism, microcephaly, hypotonia and MRI-brain abnor-
malities (e.g. thinning of the corpus callosum and cerebral
atrophy). Visual and skeletal defects may be present, but
further data is required to determine how specific these are in
relation to SLC35A2.
In this respect, we provide evidence that cortical visual
impairment is part of the phenotypic spectrum. Additionally,
congenital cardiac disease may be part of the extended
phenotype. Further patient series of this nature are required
to understand the natural history and course of the seizure
phenotype in patients with rare genotypes, such as those with
pathogenic variants in SLC35A2.Conflicts of interest
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